JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: In Vitro Activity

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021). Lead Author: Michael Huband, IDWeek 2022, October 19-21, Washington DC.

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe by Shortridge D, Deshpande L, Streit J, and Castanheira M in JAC – Antimicrob. Resist. 2022; 4 (5): dlac097.

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries. Lead author: SJ Ryan Arends, presented by C Ress at German Society for Urology 2022, September 21-24, Hamburg, Germany

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019)

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019) by Carvalhaes CCG, Sader HS, Rhomberg PR, Castanheira M, DeVries S, Mendes RE in Pediatr. Infect. Dis. J. 41(9):2022, 731-735.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii by Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, Cohen-Kutner M, Bachnoff N in antibiotics 11 (2022): 201.

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes by Mendes RE, Rhomberg, PR, Watters AA, Castanheira M in J. Antimicrob. Chemother. 77(3): 2022, 689-694.

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis. Lead author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source. Lead author: Leonard Duncan presented at ASM Microbe 2022, June 9-13, Washington DC

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model presented by M Castanheira at ASM Microbe 2022, June 9-13, Washington DC

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity presented by SJ Ryan Arends at ASM Microbe 2022, June 9-13, Washington DC.

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates. Lead Author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species. Lead author SJ Ryan Arends. Presented at ASM Microbe 2022, June 9-13, Washington DC

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms by Pfaller MA, Li L, Liu Q, Zhang J, Huband MD, Lindley JM, Mendes RE in J. Glob. Antimicrob. Resist. 3(4): 2021, dlab177.

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria by Duncan LR, Wang W, Sader HS in Antimicrob. Agents Chemother. 2022; 66 (5): 10.1128.

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020 by Duncan LR, Hamed KA, Smart JI, Pfaller MA, Flamm RK, Mendes RE published in Diagn. Microbiol. Infect. Dis. 2022; 103: 115713.

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing by Sader HS, Lindley J, Deshpande LM, Doyle T, Castanheria M. in Diagn. Microbiol. Infect. Dis. 2002; 103 (2) 115673.

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020) by Sader, HS, Castanheira, M, Huband MD, Shortridge, D, Carvalhaes, CG, Mendes, RM in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41, 867-873.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. By Shortridge D, Streit JM, Mendes R, and Castanheira M published in Microbiol. Spectr. 2022; 10 (2),  e02712-21.

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020. Lead author: SJ Ryan Arends. Japanese Association of Infectious Diseases (JAID) 22-23 April 2022.

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units. Lead author: HS Sader presented at American Thoracic Society May 13-18, 2022, San Francisco, CA, USA

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1119

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020)

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1163

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms

Activity of Meropenem Combined with the β-Lactamase Inhibitor Xeruborbactam and Comparator Agents Tested Against Challenging Gram-negative Organisms. Lead author: M Castanheira presented at European Congress of Clinical Microbiology and Infectious Diseaes (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01593

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #00563

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected Worldwide During 2019-2021. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01015

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020)

Activity of Meropenem-Vaborbactam and Comparators Against European Carbapenem-Resistant Enterobacterales Isolates Producing KPC Carbapenemase (2018-2020). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #567

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology

Evaluation of Gepotidacin Activity when Combined with Select Antimicrobial Agents and Tested Against Bacterial Isolates Using Checkerboard Methodology. Lead author: SJR Arends presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #L0184

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates

Activity of Cefiderocol and Comparators against European Enterobacterales including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1050

Lefamulin Activity against a Contemporary Global Collection of Staphylococcus aureus (SENTRY 2020-2021)

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1128

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. by Castanheira M, Doyle TB, Deshpande LM, Mendes RE and Sader HS. published in Int. J. Antimicrob. Agents. 2021; 58 (5): 106439

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020)

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020), Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL

Minocycline activity against unusual clinically significant Gram-negative pathogens

Minocycline activity against unusual clinically significant Gram-negative pathogens. by Shortridge D, Arends SJR, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother.
2021; 65 (11): e01264

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020. Lead author: LR Duncan presented at IDWeek 2021 September 29-October 3, Virtual Conference

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020)

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020)

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia. Lead author: D Shortridge presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020)

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019)

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals. Lead author: D Shortridge, presented at IDWeek 2021, September 29-October 3, Virtual Conferece

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19)

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). by Shortridge D, Carvalhaes C, Deshpande L and Castanheira M. published in J Antimicrob Chemother. 2021; 76 (10): 2600-2605